Co mbination of orally administered Non-steroidal antiinflammatory drugs and non pharmacolog ical intervention play an important role in the symptomatic management of osteoarthritis. The ideal agent should have good efficacy and low propensity to cause adverse effects.
While NSA IDs are effective in the management of pain and inflammat ion in a large number of conditions including osteoarthritis, it is now well established that they are associated with development of upper gastrointestinal damage, including mucosal erosions, ulcers and life threatening conditions like perforation and hemorrhage. This led to the development of cyclo-oxygenase-2 inhibitors. The potential advantage of COX-2 inhibitor is that they have fewer adverse effects on the gastrointestinal tract as a result of having less inhibitory effect on the gastro-protective prostanoids produced by COX-1 en zy me in the gastrointestinal tract. This advantage of COX-2 selective NSAIDs has been demonstrated in many trials. [3] [4] [5] However the cardiovascular safety of these drugs was found to be controversial. Three independent randomized trials and a cumu lative meta-analysis confirmed excess cardiovascular risk as well as serious skin reactions were also seen with rofeco xib and valdeco xib. 6, 7 Diclofenac is an already established Non-steroidal antiinflammatory drug with analgesic and antipyretic properties. Diclofenac inhibits cyclo-o xygenase activity with reduction in the tissue production of prostaglandins. It reduces joint swelling and relieves pain so is used in the treatment of rheumatoid arthritis and osteoarthritis. But studies on Diclofenac has shown increased incidence of adverse effects like abdominal pain, dyspepsia, diarrhoea, heartburn and GI u lcer.
Aceclofenac is an effective analgesic and antiinflammatory agent; through these properties it provides greater symptomat ic relief in a variety of painful conditions. 8 It has also shown to exert effects on a variety of mediators of inflammation. The drug inhibits synthesis of inflammatory cytokines like interleu kin (IL) -1β and tumor necrosis factor (TNF) and inhibits prostaglandin E2 (PGE2) production. The mode of action of Aceclofenac has been recently clarified in that the compound was shown to elicit preferential inh ibition of COX-2 as a result of limited but sustained biotransformation to Diclofenac. 9 The present study was carried out to evaluate the efficacy and Safety of Aceclofenac for the treatment of osteoarthritis compared to Diclofenac.
MATERIALS AND METHODS:

Subjects:
The study was conducted on 140 patients aged 40-60 years with a history, symptoms and signs of osteoarthritis, radiologically d iagnosed with osteoarthritis of knee, minimu m Western Ontario MacMaster (WOMA C) Index of 40, Visual Analogue scale (VAS) score of 4mm with normal haematology, renal function test and liver function test values were recruited fro m the Orthopaedic outpatient
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Study design:
The present study is a randomized, single blinded, parallel group comparative clin ical study between Diclofenac and Aceclofenac in osteoarthritis of knee. The study was approved by Institute Ethical Co mmittee and procedures followed in this study are in accordance with the ethical standards laid down by ICM R's Ethical guidelines for biomed ical research on human subjects (2006). A written informed consent was taken fro m all the patients included in the trial after explaining the patient's diagnosis, the nature and purpose of a proposed treatment, the risks and benefits of a proposed treatment (Diclofenac/ Aceclofenac) and alternative treatment (Cort icosteroids). After randomizat ion by computer generated random numbers (done online: www.randomization.co m), 140 patients who participated in the study were div ided into two groups; 70 patients were assigned to receive Diclofenac 75mg twice daily and 70 patients received Aceclofenac 100mg twice daily for a period of 8 weeks. Du ring the screening visit, informat ion on their demographic characteristics, medical history and previous current medications was collected. A thorough physical examination and baseline laboratory investigations were carried out. At 8 weeks follow up, physical examination and baseline investigation were repeated and all post drug symptoms were recorded
Efficacy measures:
WOMAC Osteoarthritis Index was ad ministered at both clin ical v isits, evaluating the following domains: pain, stiffness and difficu lty performing daily activities using a battery of 24 questions. Every question was rated fro m 'none (0)', 'mild (1)', 'moderate (2)', 'severe (3)' and 'very severe (4)'.
Visual Analog Scale bypasses the cognitive level of brain and gives a true representation of pain. Sympto m score for pain on 0-10mm VA S was calculated for weight bearing, pain at rest and active movement
The patient was made to walk a distance of 100 feet and time taken was noted in seconds. The patient rated the overall response of his or her OA to study medications on a 0-4 Likert scale ('none', 'Poor', 'moderate', 'good', and 'excellent'). The investigator rated the overall assessment of disease status on a 0-4 Likert scale ('very poor', 'poor', 'moderate', 'well' and 'very well'). The investigator rated the response of the patient's OA to study medicat ion on a 0-4 Likert scale ('none', 'Poor', 'moderate', 'good', and 'excellent'). Assessment of joint tenderness on 0-3 scale ('no pain ', 'pain', 'pain and wincing' and 'withdrawal').
Safety measures:
Safety was assessed on the basis of the adverse events reported, or by comparing the baseline symptoms with post-drug symptoms, or changes in vital signs, and physical examination findings recorded before and after the end of treatment. All reported adverse drug reactions were graded according to Co mmon To xicity Criteria (CTC) and co mpared between the groups.
Statistical analysis:
Statistical Package for Social Sciences (SPSS) version 17.0 software was used for analyzing results . Statistical test conducted were Paired t-test, Un-paired t-test, Pearson chi-square test and Fisher's exact test. Interval data have been expressed as Mean ± SD. P value < 0.05 was considered statistically significant.
RES ULTS:
In our study the two groups were homogenous with respect to baseline demographic data. At follow-up, 22 were lost and total 118 patients (60 in Aceclofenac group and 58 in Diclofenac group) completed the study. Among 140 patients, 86 patients (61.42%) were female and 54 patients (38.58%) were male. The mean age was 52.80 ± 4.55 years in Diclofenac group and 53.61 ± 5.64 years in Aceclofenac group. 
Data are in Mean ± SD, $=Paired t-test, = Unpaired t-test
The changes in WOMAC osteoarthritis index scores, joint tenderness score, investigators assessment of disease status score and response to therapy and patient's response to drug in both Diclofenac and Aceclofenac groups were statistically significant by paired t-test and when the same parameters were co mpared at 2 nd visit between Diclo fenac and Aceclofenac groups by unpaired t-test, there was significant difference between the groups. Both Aceclofenac and Diclofenac were equally effect ive in significantly reducing VAS pain score during weight bearing, at rest and during active movement, and also time taken to walk 100 feet distance. In our study all the reported side effects were of grade 1 (mild), according to CTC grading of adverse drug reactions. No clinically significant post-treatment changes were observed in haematology, renal function test and liver function test in any of the patients. The overall incidence of adverse effects was 29.4% in Diclofenac group and 11.7% in Aceclofenac group. To compare the incidence of adverse effects of two groups Fischer's Exact test was done and it was found to be statistically significant in Diclo fenac group(p=0.02). 
DISCUSS ION:
Treating the symptoms of osteoarthritis and ensuring a decent quality of life to the patients is challenging to the physician. Increasing understanding of the pathophysiological mechanism in the last few decades have revealed the use of different NSAIDS in the treat ment of osteoarthritis.
In our study improvement was seen in all three domains and overall WOMA C osteoarthritis index with both the drugs. But the improvement with Aceclofenac was found to be better in comparison to Diclofenac. The find ings of our study are similar to that of the previous studies done by Pareek A et al 2006. 10 Both the drugs are almost equally effective in reducing pain score during weight bearing, at rest and on active movement by visual analogue scale. Our results are comparable with the study done by Pareek A et al 2006 and Ward DE et al 1995. 10, 11 In our study Aceclofenac is superior to Diclofenac in decreasing jo int tenderness score similar to previous studies by Pareek A et al 2006 and Ward DE et al 1995. 10,11 Aceclofenac was better than Diclofenac in imp roving the disease and investigator response to therapy, which is supported by previous studies done by Ward DE et al 1995. 11 Patient response to Aceclofenac was better than Diclofenac which is supported by previous studies done by Ward DE et al 1995 , Wassif et al 1992 , Accardo S et al 1995 The superiority of Aceclofenac in our study may be attributed to its stimulatory effect on cartilage matrix synthesis by inhibit ing IL-β. There is evidence that Aceclofenac stimulates the synthesis of IL-1 receptor antagonist in human articu lar chondrocyte subjected to inflammatory stimuli 14 and that 4-hydroxyaceclofenac has chondroprotective properties attributed to suppression of IL-1β mediated pro matrix metalloproteinase production and proteoglycan release. 15, 16 In vitro data has shown that, there is stimu lation of glycosaminoglycan synthesis in human osteoarthritic cartilage by Aceclofenac. The antiinflammatory effects of Aceclofenac have been shown due to inhibition of various mediators like IL-1β, IL-6 and tumor necrosis factor in human osteoarthritic synovial cells and human articu lar chondrocytes, inhibition of PGE2 via cyclooxygenase inhibition (COX-1 & COX-2) after intracellular metabolism to 4 hydro xy-aceclofenac and Diclofenac in hu man rheumatoid synovial cells and other inflammatory cells, inhibit ion of React ive o xygen species, expression of cell adhesion molecules has also been shown in human neutrophils. The overall incidence of adverse effects in our study was 29.4% in Diclo fenac and 11.7% in Aceclofenac group. Aceclofenac was well tolerated than Diclofenac in terms of epigastric discomfort, dyspepsia and abdominal pain. This is supported by previous study done by Pareek 
CONCLUS ION:
Analysis of results of all the parameters of safety and efficacy explores the probable superiority of Aceclofenac over Diclofenac in osteoarthritis. Because single blinding was a limitation, the findings of this study can be confirmed by mult icentric, rando mized, double blinded large population studies.
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